| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Sammy Saab | Q88094221 |
| Edward W. Lee | Q41347543 | ||
| P2093 | author name string | Stephen T Kee | |
| Andrew Kuei | |||
| Sung-Ki Cho | |||
| P2860 | cites work | Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion | Q87445634 |
| Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients | Q87500282 | ||
| Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience | Q83272549 | ||
| Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study | Q83570720 | ||
| Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option | Q84819047 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data | Q30662240 | ||
| The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society | Q31995716 | ||
| Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study | Q33403174 | ||
| Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study | Q33781698 | ||
| Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. | Q33880227 | ||
| Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy | Q34007924 | ||
| Renal-cell carcinoma | Q34394356 | ||
| Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? | Q34460461 | ||
| Epidemiology of primary and secondary liver cancers | Q34563350 | ||
| Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver | Q34563356 | ||
| Radioembolization of yttrium-90 microspheres for hepatic malignancy | Q34563515 | ||
| Metastatic breast cancer presenting as acute liver failure | Q34571185 | ||
| Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study | Q34596441 | ||
| Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer | Q34613161 | ||
| Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. | Q34627895 | ||
| Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. | Q34650742 | ||
| Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis | Q34874473 | ||
| Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. | Q35156142 | ||
| Liver metastases from lung cancer: is surgical resection justified? | Q35169730 | ||
| Metastatic renal cell carcinoma | Q35206797 | ||
| Regional treatment options for patients with ocular melanoma metastatic to the liver | Q35679151 | ||
| Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes | Q35815482 | ||
| Treatment for pancreatic cancer: current therapy and continued progress | Q36123815 | ||
| Surgical treatment of liver metastases from pancreatic cancer | Q36253223 | ||
| Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience | Q36253253 | ||
| Extending survival with chemotherapy in metastatic breast cancer | Q36348324 | ||
| Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines | Q36412597 | ||
| Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. | Q36482781 | ||
| Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors | Q36728823 | ||
| Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis | Q36757554 | ||
| Molecular pathways mediating liver metastasis in patients with uveal melanoma | Q37087070 | ||
| Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. | Q37376227 | ||
| A first report of radioembolization for hepatic metastases from ocular melanoma | Q37393973 | ||
| Current management of colorectal hepatic metastasis | Q37436486 | ||
| Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors. | Q37517119 | ||
| Yttrium-90 radioembolization in the management of liver malignancies. | Q37759927 | ||
| Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report. | Q37799506 | ||
| Yttrium-90 radioembolization for the treatment of primary and metastatic liver tumors | Q37845500 | ||
| A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. | Q38169587 | ||
| Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma foll | Q38181628 | ||
| Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis | Q38203465 | ||
| Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases | Q38212197 | ||
| Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study. | Q38236632 | ||
| Yttrium-90 radioembolization of hepatic metastases from colorectal cancer | Q38239688 | ||
| Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. | Q38245162 | ||
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| Survival after liver resection for secondary tumors | Q40124764 | ||
| Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. | Q40221992 | ||
| Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. | Q40315003 | ||
| Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors | Q40509316 | ||
| Improving outcomes in cholangiocarcinomas. | Q40755956 | ||
| Guidelines for resection of colorectal cancer liver metastases. | Q42150472 | ||
| 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival | Q42620081 | ||
| Yttrium-90 microsphere radioembolization for treatment of lung cancer hepatic metastases. | Q42702659 | ||
| Pancreatic metastases from renal cell carcinoma: the state of the art. | Q43000519 | ||
| A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies | Q43472111 | ||
| Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results | Q44426543 | ||
| Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy | Q44524629 | ||
| Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients | Q45168728 | ||
| Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection | Q45424625 | ||
| Long-term survival after hepatectomy for hepatic recurrence of carcinoma of the papilla of Vater | Q46679571 | ||
| Radioembolization in patients with hepatic metastases from breast cancer. | Q47746504 | ||
| Hepatic resection for metastatic renal tumors: is it worthwhile? | Q47785989 | ||
| Yttrium-90-labeled microsphere radioembolotherapy of liver-dominant metastases from thoracic malignancies | Q47845386 | ||
| Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases | Q50152364 | ||
| Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience. | Q50709219 | ||
| Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. | Q50995991 | ||
| Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. | Q51204089 | ||
| Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. | Q51322653 | ||
| Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. | Q51499185 | ||
| Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. | Q53051809 | ||
| Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver. | Q53178610 | ||
| 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. | Q53245204 | ||
| Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. | Q54761299 | ||
| Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship | Q61896779 | ||
| Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization | Q63198740 | ||
| Radioembolization of Renal Cell Carcinoma Using Yttrium-90 Microspheres | Q63198744 | ||
| Examination of patient selection and outcome for hepatic resection for metastatic disease | Q69250411 | ||
| Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate | Q69791618 | ||
| A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III) | Q71186808 | ||
| Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer | Q72082642 | ||
| The regional treatment of liver metastases from breast cancer | Q72726906 | ||
| Result of liver resection as treatment for metastases from noncolorectal cancer | Q73911585 | ||
| Resection of liver metastasis after a pancreatoduodenectomy for pancreatic cancer: a case report | Q73939611 | ||
| Molecular prognostic markers in pancreatic cancer | Q74139830 | ||
| Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? | Q74770146 | ||
| Metastasectomy for liver metastases of non-colorectal primaries | Q74829142 | ||
| Results of surgical resection of liver metastases from non-colorectal primaries | Q77443199 | ||
| Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes | Q81892958 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| yttrium | Q941 | ||
| P304 | page(s) | 8271-83 | |
| P577 | publication date | 2015-07-21 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors | |
| P478 | volume | 21 |
| Q99595716 | Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT) |
| Q40071003 | From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world |
| Q39070122 | Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma |
| Q64971763 | Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. |
| Q47321056 | Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes |
| Q91784379 | Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors |
| Q39036584 | Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma |
| Q38343357 | Treatment of Non-Colorectal Liver Metastases |
| Q33844564 | Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma |
Search more.